The results demonstrated that AML patients with high TOX expression were associated with short survival time and poor OS in the training cohort, but there was no statistically significant difference (3-year OS 23% vs. 32%, P = 0.269, Figure 3A). Here, TOX is linked to acute myeloid leukemia.